CsA therapy affects the direct and indirect antigen-presentation pathway in cardiac allograft recipients.
van Besouw
N M
NM
Department of Internal Medicine I, University Hospital Rotterdam-Dijkzigt, The Netherlands.
Vaessen
L M
LM
Balk
A H
AH
Mochtar
B
B
Claas
F H
FH
Weimar
W
W
D000938:Antigen-Presenting Cells / Q000276:immunology*; D002478:Cells, Cultured; D016572:Cyclosporine / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006084:Graft Rejection / Q000276:immunology*; D016027:Heart Transplantation / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology*; D013154:Spleen / Q000276:immunology; D013745:Tetanus Toxoid / Q000276:immunology; D014019:Tissue Donors; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D013745:Tetanus Toxoid; D016572:Cyclosporine